Foghorn Therapeutics (FHTX) Equity Ratio: 2020-2025
Historic Equity Ratio for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to -0.44.
- Foghorn Therapeutics' Equity Ratio fell 376.87% to -0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.44, marking a year-over-year decrease of 376.87%. This contributed to the annual value of -0.16 for FY2024, which is 40.62% up from last year.
- Latest data reveals that Foghorn Therapeutics reported Equity Ratio of -0.44 as of Q3 2025, which was down 29.10% from -0.34 recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Equity Ratio registered a high of 0.54 during Q1 2021, and its lowest value of -0.44 during Q3 2025.
- For the 3-year period, Foghorn Therapeutics' Equity Ratio averaged around -0.21, with its median value being -0.18 (2023).
- Per our database at Business Quant, Foghorn Therapeutics' Equity Ratio surged by 146.49% in 2021 and then crashed by 97,696.47% in 2023.
- Quarterly analysis of 5 years shows Foghorn Therapeutics' Equity Ratio stood at 0.19 in 2021, then crashed by 99.85% to 0.00 in 2022, then plummeted by 97,696.47% to -0.27 in 2023, then skyrocketed by 40.62% to -0.16 in 2024, then tumbled by 376.87% to -0.44 in 2025.
- Its Equity Ratio stands at -0.44 for Q3 2025, versus -0.34 for Q2 2025 and -0.24 for Q1 2025.